Luc Besson, director of Valerian, certainly seems to think so. And while this might only be Cara's sixth acting credit (she formerly starred in Suicide Squad, Paper Towns and Kids In Love ...

Cara Delevingne Celebrates Second Anniversary with Girlfriend Minke: 'Here's to Many More Years' Taylor Swift Supports Cara Delevingne at Her Cabaret Production in London After Madrid Eras Tour ...

Rihanna, known for her hit songs, is not only a talented singer but also an actress. She made her acting debut in 2005 on the ...

Movies can often live or die by the strength of their casting, and a major misstep in that regard can often lead to disaster.

Layered protective padding miraculously does not betray the slender silhouettes of Valerian (Dane DeHaan) and Laureline (Cara ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

By Jon Pareles, Jon Caramanica and Lindsay Zoladz Hear tracks by Megan Thee Stallion, Alessia Cara, PJ Morton and others. By Jon Caramanica, Caryn Ganz and Giovanni Russonello The annual revue ...

Cara Sapida joined the Channel 11 News team in April 2009. Before landing a job in her hometown of Pittsburgh, Cara worked as a reporter for NBC-2 in Fort Myers, Florida, and as an anchor/reporter ...

Two of the station’s primary operatives, Valerian (Dane DeHaan) and Laureline (Cara Delevingne), try to keep the peace before they unknowingly stumble upon a conspiracy that could bring down ...

Cara Delevingne, 24, starred as Enchantress ... 2017's "Tulip Fever" and will play a lead role in the upcoming sci-fi film "Valerian and the City of a Thousand Planets." Dakota Johnson, 26 ...

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...